<DOC>
	<DOCNO>NCT00005996</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . SU5416 may stop growth solid tumor stop blood flow tumor . Combining chemotherapy drug SU5416 may kill tumor cell . PURPOSE : Phase I trial study effectiveness SU5416 combine gemcitabine cisplatin treat patient advance solid tumor .</brief_summary>
	<brief_title>SU5416 Combined With Gemcitabine Cisplatin Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I. Assess toxicity pharmacokinetics SU5416 combine gemcitabine cisplatin patient advance solid tumor . II . Determine antitumor activity combination treatment regimen patient population . OUTLINE : This open label , dose escalation study SU5416 . Patients receive gemcitabine IV 30 minute follow cisplatin IV 1 hour day 1 ; SU5416 IV 70 minute day 4 ; gemcitabine IV 30 minute follow SU5416 IV 70 minute day 8 , SU5416 day 11 , 15 , 18 . Treatment repeat every 3 week maximum 6 course absence disease progression unacceptable toxicity . Following 6 course therapy , patient stable responsive disease may receive SU5416 alone day 1 , 4 , 8 , 11 , 15 , 18 every 3 week maximum 1 year . Cohorts 3-6 patient receive escalate dos SU5416 maximum tolerate dose ( MTD ) reach . The MTD define dose precede least one third patient experience dose limit toxicity . Patients follow 1 month , every 3 month . PROJECTED ACCRUAL : A total 16-30 patient accrue study .</detailed_description>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Semaxinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven advanced solid tumor may respond gemcitabine cisplatin therapy ( e.g. , esophagus , head neck , breast , ovary , bladder , nonsmall cell lung cancer ) No brain metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 8.8 g/dL Hepatic : Bilirubin le 2.05 mg/dL Renal : Creatinine great 1.8 mg/dL OR Creatinine clearance least 50 mL/min Cardiovascular : No prior myocardial infarction No severe unstable angina No history atherosclerotic coronary artery disease require coronary peripheral artery bypass surgery concurrent medication No history arrhythmia , hypertension , deep venous thrombosis No clinical evidence severe peripheral vascular disease relate diabetes mellitus Pulmonary : No history lung embolism Other : No know allergy Cremophor Cremophor base drug product No contraindication systemic gemcitabine cisplatin therapy No insulin dependent noninsulin dependent diabetes mellitus clinical evidence diabetic ulcer No active malignancy except basal cell skin cancer carcinoma situ cervix No acute chronic medical psychiatric condition laboratory abnormality would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 2 week since prior epoetin alfa , filgrastim ( GCSF ) , sargramostim ( GMCSF ) No prior antiangiogenesis therapy No prior SU5416 No concurrent immunotherapy Chemotherapy : See Disease Characteristics No 1 prior systemic chemotherapy regimen allow At least 4 week since prior systemic chemotherapy ( 6 week mitomycin nitrosourea ) No prior high dose chemotherapy At least 6 month since prior gemcitabine cisplatin responsive No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : At least 4 week since prior surgery Other : No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2000</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>